Abbott Laboratories (ABL) Stock Forecast & Price Target

24 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABL Analyst Ratings

Strong Buy

15 Buy

0 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Abbott

Laboratories

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABL Stock 12 Month Forecast

Average Price Target

€105.65

▲(15.99% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is €105.65 with a high forecast of €118.70 and a low forecast of €98.48. The average price target represents a 15.99% change from the last price of €91.08.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"73":"€73","96":"€96","119":"€119","84.5":"€84.5","107.5":"€107.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":118.6988499,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€118.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.64535814461537,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€105.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":98.47608288,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€98.48</span>\n  </div></div>","useHTML":true}}],"tickPositions":[73,84.5,96,107.5,119],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.531,83.46698845384616,86.4029769076923,89.33896536153847,92.27495381538462,95.21094226923077,98.14693072307692,101.08291917692307,104.01890763076923,106.95489608461538,109.89088453846153,112.8268729923077,115.76286144615383,{"y":118.6988499,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.531,82.46287370343195,84.39474740686391,86.32662111029586,88.25849481372781,90.19036851715975,92.12224222059172,94.05411592402366,95.98598962745561,97.91786333088757,99.84973703431952,101.78161073775146,103.71348444118343,{"y":105.64535814461537,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.531,81.91139099076923,83.29178198153846,84.67217297230769,86.05256396307693,87.43295495384616,88.81334594461539,90.19373693538462,91.57412792615385,92.95451891692308,94.33490990769232,95.71530089846155,97.09569188923078,{"y":98.47608288,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":112.698,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.752,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.221,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.407,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.804,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.993,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.024,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.159,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.86,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.876,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.156,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.531,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€118.70

Average Price Target€105.65

Lowest Price Target€98.48

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Danielle Antalffy

UBS

€118.7→€109.91

Buy

20.67%

Upside

Assigned

07/28/26

UBS Issues a Buy Rating on Abbott Laboratories (ABT)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€118.7

Buy

30.32%

Upside

Reiterated

07/17/26

Jefferies Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

Jayson Bedford

Raymond James

―

Buy

―

Reiterated

07/17/26

Abbott Laboratories (ABT) Gets a Buy from Raymond James

Adam Maeder

Piper Sandler

€101.11→€103.75

Buy

13.91%

Upside

Reiterated

07/17/26

Abbott Laboratories (ABT) Receives a Buy from Piper Sandler

Robbie Marcus

J.P. Morgan

€96.72→€105.51

Buy

15.84%

Upside

Reiterated

07/17/26

Abbott price target raised to $120 from $110 at JPMorganAbbott price target raised to $120 from $110 at JPMorgan

Larry Biegelsen

Wells Fargo

€95.84→€98.48

Buy

8.12%

Upside

Reiterated

07/17/26

Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), Insmed (INSM)

Joanne Wuensch

Citi

€94.96→€98.48

Buy

8.12%

Upside

Reiterated

07/17/26

Abbott price target raised to $112 from $108 at CitiAbbott price target raised to $112 from $108 at Citi

Josh Jennings

TD Cowen

€101.11

Buy

11.02%

Upside

Reiterated

07/16/26

TD Cowen Sticks to Its Buy Rating for Abbott Laboratories (ABT)

Travis Steed

Bank of America Securities

€101.11

Buy

11.02%

Upside

Reiterated

07/16/26

Abbott Laboratories (ABT) Receives a Buy from Bank of America Securities

Shagun Singh Chadha

RBC Capital

€114.3

Buy

25.50%

Upside

Reiterated

07/16/26

RBC Capital Sticks to Their Buy Rating for Abbott Laboratories (ABT)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

07/16/26

Analysts' Top Healthcare Picks: Alpha Tau Medical Ltd (DRTS), Abbott Laboratories (ABT)

Marie Thibault

BTIG

€115.18→€117.82

Buy

29.36%

Upside

Reiterated

07/16/26

Analysts Are Bullish on Top Healthcare Stocks: Intuitive Surgical (ISRG), Abbott Laboratories (ABT)

Vijay Kumar

Evercore ISI

€105.51→€98.48

Buy

8.12%

Upside

Reiterated

07/06/26

Abbott price target lowered to $112 from $120 at Evercore ISIAbbott price target lowered to $112 from $120 at Evercore ISI

David Rescott

Robert W. Baird

€106.39

Buy

16.81%

Upside

Initiated

06/30/26

Abbott initiated with an Outperform at BairdAbbott initiated with an Outperform at Baird

David Roman

Goldman Sachs

€106.39→€99.36

Buy

9.09%

Upside

Reiterated

05/31/26

Abbott Laboratories: Buy Rating Reaffirmed on Improving 2026 Growth Outlook and Margin Expansion Potential, with Price Target Trimmed to $113

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Danielle Antalffy

UBS

€118.7→€109.91

Buy

20.67%

Upside

Assigned

07/28/26

UBS Issues a Buy Rating on Abbott Laboratories (ABT)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€118.7

Buy

30.32%

Upside

Reiterated

07/17/26

Jefferies Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

Jayson Bedford

Raymond James

―

Buy

―

Reiterated

07/17/26

Abbott Laboratories (ABT) Gets a Buy from Raymond James

Adam Maeder

Piper Sandler

€101.11→€103.75

Buy

13.91%

Upside

Reiterated

07/17/26

Abbott Laboratories (ABT) Receives a Buy from Piper Sandler

Robbie Marcus

J.P. Morgan

€96.72→€105.51

Buy

15.84%

Upside

Reiterated

07/17/26

Abbott price target raised to $120 from $110 at JPMorganAbbott price target raised to $120 from $110 at JPMorgan

Larry Biegelsen

Wells Fargo

€95.84→€98.48

Buy

8.12%

Upside

Reiterated

07/17/26

Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), Insmed (INSM)

Joanne Wuensch

Citi

€94.96→€98.48

Buy

8.12%

Upside

Reiterated

07/17/26

Abbott price target raised to $112 from $108 at CitiAbbott price target raised to $112 from $108 at Citi

Josh Jennings

TD Cowen

€101.11

Buy

11.02%

Upside

Reiterated

07/16/26

TD Cowen Sticks to Its Buy Rating for Abbott Laboratories (ABT)

Travis Steed

Bank of America Securities

€101.11

Buy

11.02%

Upside

Reiterated

07/16/26

Abbott Laboratories (ABT) Receives a Buy from Bank of America Securities

Shagun Singh Chadha

RBC Capital

€114.3

Buy

25.50%

Upside

Reiterated

07/16/26

RBC Capital Sticks to Their Buy Rating for Abbott Laboratories (ABT)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

07/16/26

Analysts' Top Healthcare Picks: Alpha Tau Medical Ltd (DRTS), Abbott Laboratories (ABT)

Marie Thibault

BTIG

€115.18→€117.82

Buy

29.36%

Upside

Reiterated

07/16/26

Analysts Are Bullish on Top Healthcare Stocks: Intuitive Surgical (ISRG), Abbott Laboratories (ABT)

Vijay Kumar

Evercore ISI

€105.51→€98.48

Buy

8.12%

Upside

Reiterated

07/06/26

Abbott price target lowered to $112 from $120 at Evercore ISIAbbott price target lowered to $112 from $120 at Evercore ISI

David Rescott

Robert W. Baird

€106.39

Buy

16.81%

Upside

Initiated

06/30/26

Abbott initiated with an Outperform at BairdAbbott initiated with an Outperform at Baird

David Roman

Goldman Sachs

€106.39→€99.36

Buy

9.09%

Upside

Reiterated

05/31/26

Abbott Laboratories: Buy Rating Reaffirmed on Improving 2026 Growth Outlook and Margin Expansion Potential, with Price Target Trimmed to $113

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

3 Months

Matthew TaylorJefferies

Success Rate

16/21 ratings generated profit

Average Return

+3.42%

Copying Matthew Taylor's trades and holding each position for 3 Months would result in 76.19% of your transactions generating a profit, with an average return of +3.42% per trade.

1 Year

Jayson BedfordRaymond James

Success Rate

35/44 ratings generated profit

Average Return

+15.80%

Copying Jayson Bedford's trades and holding each position for 1 Year would result in 79.55% of your transactions generating a profit, with an average return of +15.80% per trade.

2 Years

Matthew TaylorJefferies

Success Rate

15/21 ratings generated profit

Average Return

+29.83%

Copying Matthew Taylor's trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +29.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABL Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABL has received 34 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ABL average Analyst price target in the past 3 months is 105.65.

Each month's total comprises the sum of three months' worth of ratings.

ABL Financial Forecast

ABL Earnings Forecast

Next quarter’s earnings estimate for ABL is €1.25 with a range of €1.23 to €1.27. The previous quarter’s EPS was €1.15. ABL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 37.50% of the time in the same period. In the last calendar year ABL has Performed in-line its overall industry.

ABL Sales Forecast

Next quarter’s sales forecast for ABL is €11.42B with a range of €11.34B to €11.57B. The previous quarter’s sales results were €11.07B. ABL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 51.35% of the time in the same period. In the last calendar year ABL has Performed in-line its overall industry.

ABL Stock Forecast FAQ

What is DE:ABL’s average 12-month price target, according to analysts?

Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 105.65.

What is DE:ABL’s upside potential, based on the analysts’ average price target?

Abbott Laboratories has 15.99% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Abbott Laboratories a Buy, Sell or Hold?

Abbott Laboratories has a consensus rating of Strong Buy, which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.

What is Abbott Laboratories’s share price target?

The average share price target for Abbott Laboratories is 105.65. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €118.70 ,and the lowest forecast is €98.48. The average share price target represents 15.99% Increase from the current price of €91.08.

What do analysts say about Abbott Laboratories?

Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of Abbott Laboratories?

To buy shares of DE:ABL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Abbott Laboratories (ABL) Stock Forecast & Price Target

ABL Analyst Ratings

ABL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Abbott Laboratories

ABL Analyst Recommendation Trends

ABL Financial Forecast

ABL Earnings Forecast

ABL Sales Forecast

ABL Stock Forecast FAQ

Detailed List of Analyst Forecasts